Sophie Jacq Lapointe has been appointed by the new Board of Directors, as Chairman of the Board of Directors, succeeding Mr. Khoso Baluch. Mr. Thomas Kuhn also informed the Board of Directors of his resignation from his position as Chief Executive Officer, with immediate effect as of July 31, 2025. The Board of Directors then unanimously appointed Mr. Nicolas Trouche as Chief Executive Officer of the Company. Sophie Jacq Lapointe With over 20 years of experience in the pharmaceutical industry, Sophie has held numerous executive roles and has contributed to many commercial successes in oncology, immunology, neuroscience, rare diseases, and endocrinology. She has led or been involved in more than twenty product launches in France, across Europe, and in emerging markets, during her time at Roche, Sanofi, and Ipsen. This includes major R&D transformation projects at Sanofi and Ipsen, as well as serving as General Manager for the Belgium–Luxembourg region at Ipsen and the biotech company Perha Pharmaceuticals.